ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• RWD For Early Clinical Development Planning And Strategy

  Delve into this use case where Citeline’s Real-World Data was used to inform clinical development strategy and differentiate target product profiles through patient journey mapping.

• When "Everything" Is The Pain Point: Rethinking RTSM For Real-World Use

  RTSM friction often comes from complexity, limited flexibility, and siloed data. Discover approaches that improve visibility, forecasting, and operational efficiency across clinical trials.

• Unlocking The Power Of Real-World Evidence In FDA Submissions

  Understand the gaps between how data is collected in real-world evidence (RWE) and randomized clinical trials (RCT) and how RWE is quickly finding ways to catch up.

• Reinventing Prostate Cancer Diagnostics With An All-In-One Platform

  Discover how a lean research team saved an estimated $100k and reached 95% data compliance by unifying their clinical workflow.

• Why Amendments Break Trials and How Elosity R3 Fixes It

  Protocol amendments are inevitable. The challenge is managing them without disrupting trial execution.

• Drive Innovation In Clinical Trial Software: 3 Trends You Need To Watch

  The clinical trial landscape is undergoing a transformative shift as technology increasingly shapes study design and execution. Explore three pivotal trends that are driving this evolution.

• Why Real-Time eCOA Data Matters More Than Ever

  Real-time eCOA data enables faster eligibility decisions, proactive issue alerts, and streamlined operations by unifying data, improving precision, responsiveness, and trial execution efficiency.

• It's Official: CRIO Sites Are Now 25% Of US Sites On Chronic Condition Studies

  CRIO continues to lead the U.S. eSource market, with its platform widely adopted across clinical research sites. A recent analysis of 50 Phase 2 and 3 studies showed that, on average, 28% of U.S. sites were CRIO clients, with even higher adoption in key therapeutic areas.

• The Significance Of Quality Data In Meeting FDA Regulatory Scrutiny

  Data Science expert Rod McGlashing explains how scrutiny from the FDA spurs regulatory compliance, resulting in better data quality and the creation of optimal applications for intellectual property.

• Why eSource: The Advantages of Abandoning Paper Records

  Eliminate transcription errors and fully leverage supporting eClinical technology to provide a reliable consistent exchange of information.